SNSE vs. XGN, CTSO, EPRX, TPST, VACC, ACRS, ANVS, GNLX, LABP, and BNTC
Should you be buying Sensei Biotherapeutics stock or one of its competitors? The main competitors of Sensei Biotherapeutics include Exagen (XGN), Cytosorbents (CTSO), Eupraxia Pharmaceuticals (EPRX), Tempest Therapeutics (TPST), Vaccitech (VACC), Aclaris Therapeutics (ACRS), Annovis Bio (ANVS), Genelux (GNLX), Landos Biopharma (LABP), and Benitec Biopharma (BNTC). These companies are all part of the "medical" sector.
Sensei Biotherapeutics (NASDAQ:SNSE) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends, valuation and community ranking.
10.5% of Sensei Biotherapeutics shares are owned by institutional investors. Comparatively, 75.3% of Exagen shares are owned by institutional investors. 25.5% of Sensei Biotherapeutics shares are owned by company insiders. Comparatively, 26.1% of Exagen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Sensei Biotherapeutics had 4 more articles in the media than Exagen. MarketBeat recorded 6 mentions for Sensei Biotherapeutics and 2 mentions for Exagen. Exagen's average media sentiment score of 0.92 beat Sensei Biotherapeutics' score of 0.12 indicating that Exagen is being referred to more favorably in the news media.
Sensei Biotherapeutics has a beta of 0.14, indicating that its stock price is 86% less volatile than the S&P 500. Comparatively, Exagen has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500.
Sensei Biotherapeutics presently has a consensus target price of $4.50, indicating a potential upside of 508.44%. Exagen has a consensus target price of $7.00, indicating a potential upside of 258.97%. Given Sensei Biotherapeutics' higher possible upside, equities analysts clearly believe Sensei Biotherapeutics is more favorable than Exagen.
Sensei Biotherapeutics has a net margin of 0.00% compared to Exagen's net margin of -34.74%. Sensei Biotherapeutics' return on equity of -46.67% beat Exagen's return on equity.
Sensei Biotherapeutics received 5 more outperform votes than Exagen when rated by MarketBeat users. Likewise, 78.13% of users gave Sensei Biotherapeutics an outperform vote while only 54.05% of users gave Exagen an outperform vote.
Exagen has higher revenue and earnings than Sensei Biotherapeutics. Exagen is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Exagen beats Sensei Biotherapeutics on 8 of the 15 factors compared between the two stocks.
Get Sensei Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNSE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sensei Biotherapeutics Competitors List
Related Companies and Tools
